Illumina Inc.

source: coverage-next-full ticker: ILMN step: "01" title: Business Overview — Illumina, Inc. created: 2026-05-29

Step 01 — Business Overview: Illumina, Inc. (ILMN)

Company Summary

Illumina, Inc. is the world's dominant provider of next-generation sequencing (NGS) technology, controlling an estimated 80%+ of the global NGS market. Founded in 1998 and headquartered in San Diego, California, the company designs, develops, manufactures, and markets integrated systems for genetic analysis — spanning instruments, consumables (reagent kits, flow cells), software, and services.

Illumina's technology underpins virtually every major advance in genomics: population-scale sequencing initiatives, oncology liquid biopsy tests, NIPT (non-invasive prenatal testing), pharmacogenomics, rare disease diagnosis, agricultural genomics, and microbiome research. Its platforms are embedded in thousands of labs across hospitals, universities, biopharma companies, and government programs globally.

Business Model

Razor-and-Blade: Illumina sells or places sequencing instruments (razors), then generates recurring, high-margin revenue from consumables — reagent kits and flow cells that customers must repurchase with each sequencing run (blades). Instruments are priced $10K–$1M+ depending on throughput; consumables generate ~70–72% of total revenue annually.

Lock-In Dynamics: Once a lab installs Illumina instruments, switching costs are extremely high:

• Retraining staff and revalidating workflows is costly and time-consuming
• Clinical labs face regulatory recertification if they switch platforms
• Decades of published scientific literature built on Illumina chemistry creates methodology lock-in
• DRAGEN bioinformatics software is deeply integrated into sequencing workflows

Segments and Product Lines

Reporting Structure

Post-GRAIL divestiture (June 2024), Illumina reports as a single operating segment (Sequencing). Revenue is broken out by product type and end market in disclosures.

Product Type Revenue (FY2025)

Key Platforms

End Market Breakdown (FY2025 est.)

• Clinical (~55%): Oncology (somatic/germline), NIPT, rare disease, pharmacogenomics
• Research (~45%): Academic, government (NIH-funded), biopharma R&D

Geographic Revenue (FY2025 est.)

GRAIL Chapter (2021–2024)

The most defining event of recent Illumina history was the GRAIL saga:

• Background: GRAIL was founded by Illumina in 2016 as a spin-off focused on multi-cancer early detection using liquid biopsy. Illumina re-acquired GRAIL in August 2021 for ~$8.0B.
• Regulatory opposition: The FTC and EU Competition Commission opposed the acquisition. The EU blocked it outright; the FTC issued an administrative complaint. Illumina defied the EU Order — a historic confrontation that generated billions in fines and massive board/management distraction.
• Board/CEO turnover: CEO Francis deSouza resigned in June 2023 after shareholder pressure. Carl Icahn waged a proxy campaign, placing new board members. The board undertook a strategic review.
• Divestiture: In October 2023, Illumina announced it would divest GRAIL. The divestiture was completed June 24, 2024: 85.5% of GRAIL was spun off to Illumina shareholders as GRAIL stock (now trading NASDAQ: GRAL); Illumina retained ~14.5%.
• Financial damage: Cumulative impairments on GRAIL exceeded $4B. Operating losses from GRAIL 2021–2024 were substantial. The distraction cost Illumina strategic execution during a critical window of NovaSeq X launch.

Strategic Positioning Post-GRAIL

Under CEO Jacob Thaysen (appointed August 2023, permanent appointment March 2024):

1. Focus on core sequencing: Simplifying portfolio, driving NovaSeq X adoption
2. Cost discipline: R&D rationalized from 27% to 22% of revenue; SG&A flat
3. Clinical acceleration: Building out oncology, NIPT, and rare disease pathways
4. Multiomics: SomaLogic acquisition (closed Jan 2026) adds proteomics capability — positioning for integrated multi-omics workflows
5. China mitigation: Driving ex-China growth to offset ongoing headwinds from UEL designation

Key Customers

• Large genome centers (BGI/CNGB, Genomics England, Garvan Institute)
• Reference laboratories (LabCorp, Quest, Sonic Healthcare, Mayo Clinic)
• Hospital/health system labs (mass adoption for oncology testing)
• Academic research institutions (MIT, Broad Institute, Wellcome Sanger)
• Pharmaceutical and biotech companies (drug discovery, companion diagnostics)
• Government programs (NIH, UK Biobank, All of Us Research Program)

Competitive Position Summary

Illumina occupies a near-monopoly position in short-read NGS with ~80%+ market share. The company benefits from:

• 25+ years of installed base and consumable dependency
• Industry-standard chemistry (SBS — sequencing by synthesis)
• IP portfolio of 3,000+ patents
• Trusted brand in regulated clinical markets
• Scale advantages in manufacturing and R&D

source: coverage-next-full ticker: ILMN step: "04" title: Financial Snapshot — 5-Year P&L Summary created: 2026-05-29

Step 04 — Financial Snapshot: 5-Year P&L Summary

Key Caveat: GRAIL Distortion

FY2021–FY2024 financials are heavily distorted by GRAIL (acquisition August 2021, divestiture June 2024). GAAP operating income and net income reflect massive impairment charges ($3.9B in FY2022, additional impairments in FY2023), GRAIL operating losses, and a disposal loss in FY2024 Q2. Adjusted/core metrics are the most relevant for ongoing analysis. FY2025 is the first clean year as a pure-play sequencing company.

Income Statement Summary (GAAP)

Notes on GAAP distortions:

• FY2021 net income positive despite operating losses — reflects deferred tax benefits and other items
• FY2022 operating loss: includes ~$3.9B goodwill impairment on GRAIL
• FY2023 operating loss: includes ~$700M+ additional impairments and GRAIL operating losses
• FY2024 Q2 operating loss: ~$1.7B disposal loss on GRAIL divestiture
• FY2024 Q3 operating income spike ($741M in one quarter) reflects GRAIL derecognition gain

Adjusted (Non-GAAP) Operating Income — Core Business

Exclusions from Non-GAAP: Stock-based compensation (~$300–400M/yr), amortization of acquired intangibles, GRAIL-related items, restructuring charges, impairments

Gross Margin Analysis

Core gross margin expanded from ~60.9% (FY2023 trough, GRAIL-burdened) to 66.1% (FY2025, clean). Management targets 68–70% longer-term as NovaSeq X consumables mature.

Operating Expense Trends

Key insight: R&D rationalization from 30% → 22% of revenue is the largest driver of the EBIT margin recovery. Management target is ~22–24% R&D long-term while maintaining innovation pace.

P&L Summary Table (FY2025 — Clean Year)

Key Financial Ratios (FY2025 / TTM)

Financial Health Assessment

Strengths:

• Revenue stabilized at $4.3–4.4B; returning to growth in FY2026
• Gross margin recovery underway (60.9% trough → 66.1% → targeting 68–70%)
• FCF generation strong and improving ($283M → $709M → $931M in 3 years)
• Operating leverage now flowing through as GRAIL costs eliminated
• Balance sheet: $1.6B cash, $1.5B LT debt — manageable

Risks:

• Revenue near peak (FY2021 was $4.5B; FY2025 still slightly below)
• R&D cuts could be short-sighted if competitive threats accelerate
• SomaLogic integration adds complexity and integration risk to clean story
• China revenue headwinds persist

Verdict: The GAAP P&L is finally clean. Illumina's core economics — 66%+ gross margins, 22%+ EBIT margins on normalized basis, 21%+ FCF margins — are exceptional for an instrument company. The path to 26% EBIT margin (management 2027 target) is credible via continued consumable mix-up and OpEx leverage.

source: coverage-next-full ticker: ILMN step: "12" title: Catalysts & Scenarios created: 2026-05-29

Step 12 — Catalysts & Scenarios

Near-Term Catalysts (6–18 months)

1. FY2026 Revenue Guidance Achievement / Raise

• Management guided $4.5–4.6B (+4–6% YoY); upside to $4.65–4.7B would drive 5–8% stock appreciation
• Q2 2026 earnings (August 2026) will be the first meaningful test of full-year trajectory
• Consumable revenue per NovaSeq X instrument is the key watch metric

2. Operating Margin Expansion Toward 26% Target

• Management 2027 target of 26% EBIT margin; any quarter printing 22–23%+ non-GAAP margins ahead of schedule drives re-rating
• R&D efficiency (22% of rev holding while absolute OpEx flat) + operating leverage from revenue growth = path to 24%+ in FY2026

3. NovaSeq X Consumable Ramp — Gigabase Data Points

• Each quarterly earnings call includes gigabase shipment commentary
• Achieving >80% of gigabases from NovaSeq X would signal consumable monetization fully realized → consensus estimate upgrades

4. Clinical Adoption Milestones (Population Programs)

• New national sequencing programs announcement (India, Saudi Arabia, UAE at scale)
• Expansions to existing programs (NHS England, US All of Us)
• Multi-year, high-volume contracts with major diagnostic labs (LabCorp, Quest equivalent outside US)

5. SomaLogic Integration Progress (FY2026 H2)

• Successful product integration milestone: first combined "genomics + proteomics" offering commercially launched
• SomaLogic revenue contribution ramping above initial guidance (~$60–80M)
• Demonstration of multiomics synergy (e.g., partnership with Roche, AstraZeneca for integrated research workflows)

6. China Stabilization / Resolution

• An unexpected improvement in US-China trade relations or removal from UEL list would be a $200–300M revenue upside catalyst
• Probability: LOW (~10–15%) in 12-month timeframe; but asymmetric upside if it occurs

7. Capital Return Announcements

• Initiation of regular dividend (unlikely near-term, but would be a signal of FCF confidence)
• New/expanded buyback authorization (likely in 2027 as FCF grows further)
• Special dividend from excess cash balance

Medium-Term Catalysts (18–48 months)

1. 2027 EBIT Margin Target Achievement

• 26% EBIT margin by 2027 = ~$1.2B EBIT on ~$4.8B revenue
• At 25x forward P/E (non-GAAP EPS ~$7.50) → stock price ~$187 (from current $158)
• At 30x P/E → $225 — significant upside if multiple expansion accompanies execution

2. Long-Read Platform Response

• Illumina launching a credible long-read or hybrid platform would remove a significant overhang
• "Illumina Complete Long Read" commercial traction (current synthetic long-read approach) could prove viable

3. AI-Genomics Demand Surge

• Major AI drug discovery programs (Isomorphic, Recursion, Genentech) ramping genomic data production
• Pharmaceutical companies building large-scale human genome databases as AI training data
• This could add 5–10%+ to consumable demand if the AI-genomics data flywheel accelerates

4. Rare Disease WGS Standard-of-Care Shift

• If WGS becomes reimbursed first-line test for rare/undiagnosed disease patients (UK NICE precedent, US Medicaid expansion), this unlocks a large clinical volume
• ILMN would be the primary beneficiary; could add $300–500M to addressable market over 3–5 years

Scenario Analysis

Base Case (Probability: 55%)

• FY2026: Revenue $4.55B; EBIT margin 21–22%; EPS (non-GAAP) $5.10–5.20
• FY2027: Revenue $4.8B; EBIT margin 24–26%; EPS $6.50–7.00
• Multiple: 25–28x forward P/E
• Price Target: $170–185 (12 months); $200–220 (24 months)

Bull Case (Probability: 25%)

• NovaSeq X consumable ramp exceeds expectations; clinical segment grows 20%+
• SomaLogic integration creates differentiated multiomics revenue
• NIH headwinds resolve; research segment returns to growth
• 26% EBIT target achieved in FY2026 rather than FY2027
• Multiple: 30–33x forward P/E on premium growth/margin profile
• Price Target: $210–235 (12 months); $250–280 (24 months)

Bear Case (Probability: 20%)

• NIH cuts materialize more severely (-30% funding); research segment contracts 10%+
• China worsens beyond guidance; UEL restrictions expand
• Element Biosciences begins winning clinical lab tenders; installed base growth slows
• SomaLogic integration disappoints; margin expansion delayed
• Multiple: 20–22x forward P/E on slower growth
• Price Target: $120–140 (12 months); $110–130 (24 months)

Bull Case

• NovaSeq X consumable ramp accelerates faster than expected as large population sequencing programs scale globally, driving EBIT margins above 26% ahead of the 2027 target and triggering consensus EPS estimate upgrades of 15%+
• Clinical segment sustains 18–20% ex-China growth as whole-genome sequencing becomes reimbursed standard-of-care for rare disease and comprehensive genomic profiling expands, significantly outpacing the research headwind from NIH uncertainty
• SomaLogic proteomics integration proves strategically differentiated, attracting major pharma partnerships for multiomics research platforms that re-rate ILMN toward a 30–33x P/E multiple on growing out-year earnings

Bear Case

• NIH budget cuts of 25–35% materialize and persist for 2–3 years, reducing research-segment volumes materially while simultaneously signaling reduced government commitment to genomics programs globally, creating a compounding headwind to both top-line and narrative
• China regulatory situation deteriorates further — MOFCOM restrictions tighten or domestic MGI alternatives gain clinical certification — accelerating revenue erosion from the $210M FY2026 baseline toward near-zero contribution over 3 years with no offsetting regional acceleration
• Element Biosciences and Ultima Genomics secure their first FDA clearances for high-throughput clinical applications by 2027–2028, initiating a competitive dynamic in the most defensible segment of Illumina's installed base and triggering multiple compression from 28x to 18–20x forward earnings